Pipeline
Addressing a range of degenerative retinal diseases
Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics
Indication
Product Candidate
Discovery
Ind enabling phase
Phase 1
Retinitis Pigmentosa
Genotype agnostic
RTx-015
IND Enabling Phase
Other Inherited retinal degenerations
Stargardt’s disease
RTx-015
IND Enabling Phase
Geographic Atrophy
RTx-021
Discovery